Corporate Complicity Index
CCI

Company Directory

Company Directory

Company Directory - Absci

Company Details - Absci

Absci Logo

Absci

Website

Absci is a biotechnology company that utilizes artificial intelligence to accelerate drug discovery and development.

CCI Score

CCI Score: Absci

11.46

-0.02%

Latest Event

Absci Partners with AstraZeneca for AI-Enabled Oncology Design

Absci has entered a deal with AstraZeneca, valued at up to $247 million, to collaborate on designing an anti-cancer antibody using AI-driven technology. This collaboration reinforces Absci’s role in accelerating innovative drug discovery and development.

Take Action

So what can you do? Support by shopping, spreading the word, or offering your support.

Shop Alternatives
SEE ALL
MethaneSAT
Colossal
Verve
Use Your Voice
OTHER TOOLS
Investigate
Share the Score
SUPPORT CCI

SABOTEUR

Absci is currently rated as a Saboteur.

+10 to +24 CCI Score
Companies in this bracket take more subtle actions to undermine authoritarian practices. They might implement internal policies or support reforms that quietly weaken oppressive systems, contributing to change in less overt ways.

Latest Events

  • Absci Partners with AstraZeneca for AI-Enabled Oncology Design Logo
    DEC
    04
    2023
    Absci Partners with AstraZeneca for AI-Enabled Oncology Design

    65.37

    Absci has entered a deal with AstraZeneca, valued at up to $247 million, to collaborate on designing an anti-cancer antibody using AI-driven technology. This collaboration reinforces Absci’s role in accelerating innovative drug discovery and development.

  • +70

    Business Practices and Ethical Responsibility

    April 11

    The deal exemplifies responsible business practices and ethical collaboration with a major pharmaceutical player, demonstrating a commitment to advancing healthcare and drug discovery in a transparent and socially beneficial manner.

    AstraZeneca signs $247M AI-enabled oncology antibody design pact

  • +80

    Technology and Services Impact

    April 11

    Absci’s utilization of AI to design de novo antibodies in collaboration with AstraZeneca highlights a strong commitment to technological innovation in biotech, supporting progressive outcomes in healthcare through advanced scientific methods.

    AstraZeneca signs $247M AI-enabled oncology antibody design pact

  • Absci lays off 15% workforce Logo
    AUG
    31
    2023
    Absci lays off 15% workforce

    -42.46

    Vancouver-based biotechnology firm Absci announced in an SEC filing on August 31, 2023, that it would lay off about 15% of its worldwide staff (approximately 30 employees) as part of an organizational realignment affecting both remote and Vancouver-based workers.

  • -50

    Labor Relations and Human Rights Practices

    April 11

    The decision to lay off 15% of the workforce demonstrates a disregard for worker security and fair labor practices. Such significant cuts, even if purportedly for strategic realignment, negatively impact workers' rights and contribute to a climate of economic precarity, which is problematic from an anti-fascist, pro-worker perspective.

    Vancouver biotech firm Absci lays off 15 percent of its worldwide staff

Industries

325414
Biological Product (except Diagnostic) Manufacturing
541511
Custom Computer Programming Services
541715
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)